Abstract 360P
Background
Breast cancer is the the most frequently diagnosed cancer worldwide in women, with nearly two million new cases diagnosed in 2018. In the Philippines, breast cancer is the most common cancer among women. Upon diagnosis, the decision process differs from person to person. The patients then meet choices about surgical treatment and the need for adjuvant treatment, taking into consideration surgery, chemotherapy and radiation therapy to name a few. However, these decisions are not clear cut and a thorough discussion between the patient and the physician regarding treatment options taking into consideration the choice of the patient. This study aims to identify factors influencing treatment decisions among breast cancer patients in the Philippine General Hospital Cancer Institute - Medical Oncology Outpatient Clinic.
Methods
The study used a questionnaire and structured interview adapted from study done by Grunfeld, et.al. Descriptive statistics were utilized in the analysis of the data acquired from the recruited participants. This allowed identification of patient demographics, economic profile, cancer profile, sources of financial or medical assistance and summary of patient’s responses to identify the factors influencing treatment decisions among breast cancer patients.
Results
A total of 272 participants consented and included in the analysis of the study. This study identified high level of satisfaction with consultation to their attending physician, caring and sincere communication about prognosis and likelihood of benefit from treatment, family as person of influence, patient’s collaborative role in the decision-making process, desire of cure and trust with their doctors as factors of influence in accepting cancer treatment decisions.
Conclusions
Health practices and treatment decisions among Filipino breast cancer patients are widely affected by interplay of the following factors: family, community, doctor’s recommendations, patient’s satisfaction and participation in the decision-making, health care access and adverse treatments to name a few.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bobby de Guzman.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract